Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Al­most two years af­ter first buy­ing in­to Genor Bio­phar­ma’s pipeline of can­cer and au­toim­mune ther­a­pies, Hill­house Cap­i­tal has led a $160 mil­lion cash in­jec­tion to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER